Concepts (107)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 2 | 4 | 2024 | 690 | 1.460 |
Why?
|
| Diabetic Ketoacidosis | 2 | 2019 | 12 | 1.270 |
Why?
|
| Blood Glucose | 4 | 2021 | 485 | 1.130 |
Why?
|
| Diabetes Mellitus | 2 | 2019 | 536 | 0.880 |
Why?
|
| Thrombocythemia, Essential | 1 | 2022 | 3 | 0.790 |
Why?
|
| Primary Myelofibrosis | 1 | 2022 | 11 | 0.790 |
Why?
|
| Hyperglycemia | 2 | 2020 | 104 | 0.760 |
Why?
|
| Diplopia | 1 | 2021 | 9 | 0.750 |
Why?
|
| Diabetic Neuropathies | 1 | 2021 | 8 | 0.750 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2024 | 686 | 0.670 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2022 | 189 | 0.650 |
Why?
|
| Gastroparesis | 1 | 2019 | 8 | 0.640 |
Why?
|
| Hospitalization | 2 | 2024 | 1344 | 0.640 |
Why?
|
| Ketosis | 1 | 2019 | 3 | 0.640 |
Why?
|
| Hypoparathyroidism | 1 | 2019 | 7 | 0.620 |
Why?
|
| Colorectal Surgery | 1 | 2019 | 54 | 0.600 |
Why?
|
| Insulin | 2 | 2021 | 687 | 0.590 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2019 | 46 | 0.590 |
Why?
|
| Metformin | 1 | 2019 | 73 | 0.580 |
Why?
|
| Autoantibodies | 1 | 2019 | 182 | 0.580 |
Why?
|
| Acute Kidney Injury | 1 | 2019 | 143 | 0.540 |
Why?
|
| Autoimmune Diseases | 1 | 2019 | 231 | 0.530 |
Why?
|
| Emergency Service, Hospital | 1 | 2024 | 1070 | 0.510 |
Why?
|
| Argyria | 1 | 2013 | 1 | 0.430 |
Why?
|
| Silver Compounds | 1 | 2013 | 1 | 0.430 |
Why?
|
| Sella Turcica | 1 | 2013 | 1 | 0.420 |
Why?
|
| Dacarbazine | 1 | 2013 | 18 | 0.420 |
Why?
|
| Pituitary Neoplasms | 1 | 2013 | 21 | 0.420 |
Why?
|
| Sarcoma | 1 | 2013 | 36 | 0.410 |
Why?
|
| Complementary Therapies | 1 | 2013 | 62 | 0.400 |
Why?
|
| Glucagon | 1 | 2011 | 33 | 0.360 |
Why?
|
| Pheochromocytoma | 1 | 2011 | 26 | 0.360 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2011 | 43 | 0.350 |
Why?
|
| Agranulocytosis | 1 | 2010 | 6 | 0.350 |
Why?
|
| Methimazole | 1 | 2010 | 8 | 0.340 |
Why?
|
| Thyroid Crisis | 1 | 2010 | 5 | 0.340 |
Why?
|
| Aged | 8 | 2024 | 14254 | 0.340 |
Why?
|
| Plasmapheresis | 1 | 2010 | 18 | 0.340 |
Why?
|
| Antithyroid Agents | 1 | 2010 | 19 | 0.340 |
Why?
|
| Humans | 15 | 2024 | 62682 | 0.310 |
Why?
|
| Antineoplastic Agents | 1 | 2013 | 660 | 0.280 |
Why?
|
| Hypoglycemic Agents | 2 | 2021 | 214 | 0.280 |
Why?
|
| Retrospective Studies | 5 | 2024 | 6533 | 0.270 |
Why?
|
| Male | 8 | 2024 | 29487 | 0.210 |
Why?
|
| Hydroxyurea | 1 | 2022 | 19 | 0.200 |
Why?
|
| Female | 7 | 2024 | 32495 | 0.180 |
Why?
|
| Blood Glucose Self-Monitoring | 1 | 2021 | 62 | 0.170 |
Why?
|
| Middle Aged | 5 | 2024 | 17365 | 0.170 |
Why?
|
| Prognosis | 2 | 2022 | 1724 | 0.170 |
Why?
|
| 3-Hydroxybutyric Acid | 1 | 2019 | 2 | 0.160 |
Why?
|
| Thyroid Carcinoma, Anaplastic | 1 | 2019 | 1 | 0.160 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2019 | 16 | 0.150 |
Why?
|
| Hypocalcemia | 1 | 2019 | 16 | 0.150 |
Why?
|
| Insulin Infusion Systems | 1 | 2018 | 10 | 0.150 |
Why?
|
| Glucocorticoids | 1 | 2020 | 188 | 0.150 |
Why?
|
| Thyroid Neoplasms | 1 | 2019 | 73 | 0.150 |
Why?
|
| Coronary Angiography | 1 | 2019 | 200 | 0.150 |
Why?
|
| Cohort Studies | 1 | 2024 | 2540 | 0.150 |
Why?
|
| Income | 1 | 2019 | 169 | 0.140 |
Why?
|
| Intensive Care Units | 1 | 2021 | 405 | 0.140 |
Why?
|
| Critical Illness | 1 | 2021 | 321 | 0.140 |
Why?
|
| Pilot Projects | 1 | 2021 | 989 | 0.140 |
Why?
|
| Contrast Media | 1 | 2019 | 421 | 0.130 |
Why?
|
| Thyroidectomy | 2 | 2019 | 31 | 0.120 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2018 | 619 | 0.100 |
Why?
|
| Algorithms | 1 | 2018 | 1003 | 0.100 |
Why?
|
| Risk Assessment | 1 | 2020 | 2040 | 0.100 |
Why?
|
| Lung Neoplasms | 1 | 2019 | 658 | 0.100 |
Why?
|
| Gastrointestinal Motility | 1 | 2011 | 8 | 0.090 |
Why?
|
| Gastrointestinal Agents | 1 | 2011 | 26 | 0.090 |
Why?
|
| Thyrotoxicosis | 1 | 2010 | 7 | 0.090 |
Why?
|
| Colonoscopy | 1 | 2011 | 97 | 0.090 |
Why?
|
| Graves Disease | 1 | 2010 | 16 | 0.090 |
Why?
|
| Diagnosis, Differential | 1 | 2013 | 964 | 0.080 |
Why?
|
| Adult | 2 | 2021 | 16629 | 0.080 |
Why?
|
| Aged, 80 and over | 2 | 2019 | 5403 | 0.070 |
Why?
|
| Immunocompetence | 1 | 2003 | 21 | 0.050 |
Why?
|
| Transplantation, Heterologous | 1 | 2003 | 229 | 0.050 |
Why?
|
| Islets of Langerhans Transplantation | 1 | 2003 | 176 | 0.050 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2003 | 198 | 0.050 |
Why?
|
| Islets of Langerhans | 1 | 2003 | 279 | 0.040 |
Why?
|
| Treatment Outcome | 1 | 2010 | 5591 | 0.040 |
Why?
|
| SEER Program | 1 | 2019 | 74 | 0.040 |
Why?
|
| Thyroid Gland | 1 | 2019 | 81 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2019 | 241 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 2019 | 486 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2019 | 933 | 0.030 |
Why?
|
| United States | 2 | 2020 | 7721 | 0.030 |
Why?
|
| Incidence | 1 | 2020 | 1367 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2020 | 2445 | 0.030 |
Why?
|
| Risk Factors | 1 | 2020 | 5303 | 0.020 |
Why?
|
| Glucuronic Acid | 1 | 2003 | 19 | 0.010 |
Why?
|
| Hexuronic Acids | 1 | 2003 | 22 | 0.010 |
Why?
|
| Capsules | 1 | 2003 | 35 | 0.010 |
Why?
|
| Mice, Inbred Strains | 1 | 2003 | 189 | 0.010 |
Why?
|
| Glucose Tolerance Test | 1 | 2003 | 97 | 0.010 |
Why?
|
| Alginates | 1 | 2003 | 46 | 0.010 |
Why?
|
| Animals, Newborn | 1 | 2003 | 236 | 0.010 |
Why?
|
| Cellular Senescence | 1 | 2003 | 110 | 0.010 |
Why?
|
| Swine | 1 | 2003 | 368 | 0.010 |
Why?
|
| Cell Division | 1 | 2003 | 450 | 0.010 |
Why?
|
| Cell Survival | 1 | 2003 | 573 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 2003 | 463 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2003 | 1346 | 0.010 |
Why?
|
| Time Factors | 1 | 2003 | 3742 | 0.010 |
Why?
|
| Mice | 1 | 2003 | 10804 | 0.000 |
Why?
|
| Animals | 1 | 2003 | 20584 | 0.000 |
Why?
|